We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly scored an FDA approval Tuesday for EGFR inhibitor Portrazza in combination with chemotherapy for second-line treatment in metastatic squamous non-small cell lung cancer. Read More
The FDA gave a thumbs up Monday to BioThrax to prevent anthrax following suspected or confirmed exposure in conjunction with recommended antibiotic treatment. Read More